Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis

Washburn, Birgit; Schirrmacher, Volker

doi:10.3892/ijo.21.1.85

Cited by 71 publications

(85 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We previously identified in such supernatants Th1-cytokines such as TNF-a, interferon-g and IL-2 and the chemokines RANTES, IP-10 and interferon-a. 12 Supernatant factors with antitumor reactivity could be distinguished from cell-mediated effects of purified T cells (Fig. 6) that required cell to cell contact and which disappeared upon separation through a cellimpermeable membrane.…”

Section: Discussionmentioning

confidence: 99%

“…11 Upon infection by NDV, human tumor cells upregulate expression of HLA and cell adhesion molecules, produce interferons and chemokines and finally undergo apoptosis. 12 NDV was also shown to induce TNF-related apoptosis inducing ligand (TRAIL), which can mediate tumoricidal activity. 13 To further augment the immunogenicity of the NDVmodified autologous tumor vaccine (ATV-NDV), we constructed 2 bispecific single-chain Fv (bsscFv) antibody molecules that specifically bind to HN molecules and to either CD3 or CD28 molecules on human T lymphocytes.…”

mentioning

confidence: 99%

See 1 more Smart Citation

A tumor vaccine containing anti‐CD3 and anti‐CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes

Haas

Lulei

Fournier

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

We recently reported on newly designed virus‐targeted bispecific CD3‐ and CD28‐binding molecules for human T‐cell activation. When bound via one arm to a human virus‐modified tumor cell vaccine, these reagents caused a polyclonal T‐cell response and overcame the potential various T‐cell evasion mechanisms of tumor cells. In our current study, we demonstrated the induction of strong antitumor activity in human lymphocytes upon coincubation with a virus‐modified tumor vaccine containing anti‐CD3 and anti‐CD28 bispecific antibodies. Blood mononuclear cells or purified T cells that were coincubated with such a tumor vaccine for 3 days were able to destroy monolayers of human breast carcinoma and other carcinoma cells. Serial transfer to new tumor cell monolayers revealed antitumor cytotoxic activity in such effector cells that lasted for about 10 days. Nontumor target cells appeared to be much less sensitive to the activated effector cells. Although the bispecific molecules alone did not activate effector cells, their binding to virus‐infected tumor cells was important and more effective than their binding to free virus. Antitumor activity of the activated effector cells was mediated through soluble factors as well as through direct cell contact of effector cells with the nontargeted bystander tumor cells. Since the virus‐modified tumor vaccine is well tolerated and already exhibits a certain effectiveness in cancer patients, the combination with new bispecific molecules has the potential to introduce additional antitumor effects. The reagents can also be combined with Newcastle Disease Virus (NDV)‐based oncolytic virotherapy. © 2005 Wiley‐Liss, Inc.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

A tumor vaccine containing anti‐CD3 and anti‐CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes

Haas

Lulei

Fournier

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…11 On the basis of these preclinical observations, we subsequently established a similar autologous NDV virus-modified tumor vaccine (ATV-NDV) for human application. 2,12 Recently, we reported results from two non-randomized phase II studies, which aimed at feasibility, safety and clinical benefit. In both studies (glioblastoma multiforme (GBM) 13 and head and neck carcinoma (HNSCC) 14 ), the establishment of primary tumor cell cultures was feasible and successful in about 80-90%.…”

Section: Introductionmentioning

confidence: 99%

Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy

Janke

Peeters²,

Leeuw

et al. 2007

Gene Ther

View full text Add to dashboard Cite

“…NDV also exhibits pleiotropic immune-modulatory properties 50 and induces production of double-stranded RNA, IFNs, and chemokines in infected cells. 51 The idea to use live NDV to treat cancer dates back to the 60s, when anecdotal cases of tumor regression after exposure to viral infection were observed. 52,53 The oncolytic NDV PV701 was utilized in a phase I trial including 79 patients with various advanced solid cancers.…”

mentioning

confidence: 99%

Clinical trials of gene therapy, virotherapy, and immunotherapy for malignant gliomas

et al. 2006

View full text Add to dashboard Cite

Despite advances in surgical and adjuvant therapy, the prognosis for malignant gliomas remains dismal. This gloomy scenario has been recently brightened by the increasing understanding of the genetic and biological mechanisms at the basis of brain tumor development. These findings are being translated into innovative therapeutic approaches, including gene therapy, virotherapy, and vaccination, some of which have already been experimented in clinical trials. The advantages and disadvantages of all these different therapeutic modalities for malignant gliomas will be critically discussed, providing perspective for future investigations.

show abstract

Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis

Cited by 71 publications

References 0 publications

A tumor vaccine containing anti‐CD3 and anti‐CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes

A tumor vaccine containing anti‐CD3 and anti‐CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes

Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy

Clinical trials of gene therapy, virotherapy, and immunotherapy for malignant gliomas

Contact Info

Product

Resources

About